A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising the following:

a)    Administering a drug providing 6-thioguanine to a subject having said immune-mediated gastrointestinal disorder.
b)    Determining the level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder,

wherein the level of 6-thioguanine less than about 230 pmol per 8 × 108 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and

wherein the level of 6-thioguanine greater than about 400 pmol per 8 × 108 red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.

Adapted from Prometheus Laboratories v. Mayo Collaborative Services, No. 2008-1403.

Return to "Patent Eligibility for Personalized Medicine."